Skip to main content
S 1041 119th Congress Senate Commerce Civil actions and liability Competition and antitrust Consumer affairs Drug safety, medical device, and laboratory regulation Health care costs and insurance Inflation and prices Intellectual property Judicial review and appeals Manufacturing Prescription drugs

Affordable Prescriptions for Patients Act

Introduced: March 13, 2025 Introduced by: Cornyn, John Republican · Texas See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 10, 2025
Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.
Apr 10, 2025
Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
Apr 3, 2025
Committee on the Judiciary. Ordered to be reported with amendments favorably.
Mar 13, 2025
Read twice and referred to the Committee on the Judiciary.
Mar 13, 2025
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Affordable Prescriptions for Patients Act

This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a less expensive alternative.)

The bill's provisions apply to an existing framework that gives the biosimilar manufacturer an abbreviated path to Food and Drug Administration approval to sell the biosimilar. Specifically, if the biosimilar manufacturer completes certain actions under the framework, such as sharing certain information about its product with the reference product manufacturer, the bill limits the number of certain patents that the reference product manufacturer may assert in a lawsuit, such as patents that were filed more than four years after the reference product received market approval. The limit shall not apply to patents claiming certain methods for using the biologic drug.

The court in which the infringement lawsuit is filed may increase the limit if justice so requires or if there is good cause for the increase.

What's happening now April 10, 2025

Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.

 Hearings & markups 1
 Related & companion bills 2
  • S 891 Related bill Bipartisan Health Care Act
  • HR 1768 Related bill Lower Costs for Everyday Americans Act
 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 191

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

See all 191 filings →
 Cosponsors 3
All 3 Democratic 2 Republican 1
D
Blumenthal, Richard
Connecticut · Mar 13, 2025
 D
Durbin, Richard J.
Illinois · Mar 13, 2025
 R
Grassley, Chuck
Iowa · Mar 13, 2025
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1041: Affordable Prescriptions for Patients Act. 119th Congress. Open America. https://openamerica.io/bill/119-S-1041/
MLA
"S. 1041: Affordable Prescriptions for Patients Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-1041/.
Bluebook (legal)
S. 1041, 119th Cong. (2026), https://openamerica.io/bill/119-S-1041/.
Markdown link
[S. 1041: Affordable Prescriptions for Patients Act](https://openamerica.io/bill/119-S-1041/)
Report a problem